These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 19930733

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.
    Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C.
    Vaccine; 2009 Oct 09; 27(43):6060-79. PubMed ID: 19647813
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
    de Kok IM, Habbema JD, van Rosmalen J, van Ballegooijen M.
    Eur J Cancer; 2011 Feb 19; 47(3):428-35. PubMed ID: 20971633
    [Abstract] [Full Text] [Related]

  • 14. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
    Boot HJ, Wallenburg I, de Melker HE, Mangen MJ, Gerritsen AA, van der Maas NA, Berkhof J, Meijer CJ, Kimman TG.
    Vaccine; 2007 Aug 14; 25(33):6245-56. PubMed ID: 17630049
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Economic evaluation of human papillomavirus vaccination in developed countries.
    Brisson M, Van de Velde N, Boily MC.
    Public Health Genomics; 2009 Aug 14; 12(5-6):343-51. PubMed ID: 19684446
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ.
    Vaccine; 2008 Jul 29; 26(32):4015-24. PubMed ID: 18602731
    [Abstract] [Full Text] [Related]

  • 20. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.
    Vaccine; 2011 Oct 26; 29(46):8443-50. PubMed ID: 21816193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.